Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

scientific article

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/381202
P698PubMed publication ID14765345

P50authorBenjamin P. HowdenQ37837894
Tony M. KormanQ40454333
James C. HurleyQ56126227
P2093author name stringKerry Read
M Lindsay Grayson
Paul D R Johnson
Elizabeth A Grabsch
Barrie C Mayall
Patrick G P Charles
Philipp du Cros
Arthur J Morris
Jenny Robson
Sally A Roberts
Andrew Fuller
Narin Bak
Peter B Ward
P2860cites workVancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to knowQ31704853
Proposed modifications to the Duke criteria for the diagnosis of infective endocarditisQ33898620
Vancomycin resistance in staphylococciQ33906522
Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremiaQ34396414
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistanceQ34547868
Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing thQ34974539
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureusQ40542104
A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospitalQ43552304
The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic modelQ43778977
Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.Q44302673
Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterizationQ44340945
Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycinQ45199316
Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.Q54095666
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.Q55067143
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectStaphylococcus aureusQ188121
vancomycinQ424027
methicillin-resistant Staphylococcus aureusQ595158
P304page(s)521-528
P577publication date2004-01-29
P1433published inClinical Infectious DiseasesQ5133764
P1476titleTreatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility
P478volume38

Reverse relations

cites work (P2860)
Q43621611A complicated prosthetic valve endocarditis due to methicillin resistant Staphylococci treated with linezolid and ciprofloxacin: a case report
Q30455758A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin
Q37277083Acquired vancomycin resistance in clinically relevant pathogens
Q42071192Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014.
Q41999444Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations
Q36744836Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus
Q38566653An uncommon presentation for a severe invasive infection due to methicillin-resistant Staphylococcus aureus clone USA300 in Italy: a case report
Q46708063Anti-MRSA drug use and antibiotic susceptibilities of MRSA at a university hospital in Japan from 2007 to 2011.
Q41832910Antibiofilm and membrane-damaging potential of cuprous oxide nanoparticles against Staphylococcus aureus with reduced susceptibility to vancomycin
Q36338182Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection
Q36283731Antibiotic resistance in Staphylococcus aureus and its relevance in therapy
Q36325685Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci
Q37453459Assessment of therapeutic drug monitoring of vancomycin in elderly patients according to new guidelines
Q35607636Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.
Q53883692Bacterial and Lyme Arthritis.
Q54447533Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting.
Q28534516Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis
Q37238371Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy
Q36898180Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).
Q37124131Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection
Q35066896Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. au
Q38425879Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus
Q37849391Clinical management of Staphylococcus aureus bacteraemia
Q38099554Clinical management of septic arthritis
Q34157657Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children
Q36083208Clinical update on linezolid in the treatment of Gram-positive bacterial infections
Q41869403Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.
Q50080441Comment: Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin
Q36070903Community-associated methicillin-resistant Staphylococcus aureus: a review
Q37153976Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy
Q36171683Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model
Q42718716Comparison of In-vitro Activities of Linezolid and Vancomycin against Staphylococcus aureus Isolated from A Tertiary Care Hospital
Q37949553Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis.
Q41570947Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus
Q35172374Convergent adaptation in the dominant global hospital clone ST239 of methicillin-resistant Staphylococcus aureus.
Q42855424Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies
Q35026521Current and novel antibiotics against resistant Gram-positive bacteria
Q37722741Current diagnostic tools for methicillin-resistant Staphylococcus aureus infections.
Q35771368Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
Q44279637Daptomycin in complicated skin and soft tissue infections
Q36744825Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus
Q24620644Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole
Q45121503Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin
Q36969754Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression
Q41915895Development and stability studies of novel liposomal vancomycin formulations.
Q61757070Diagnose und Therapie der Sepsis
Q44754456Diagnosis and therapy of sepsis
Q33321447Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia
Q46987530Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia
Q34481625Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus
Q58762088Effects of pharmacist intervention in Vancomycin treatment for patients with bacteremia due to Methicillin-resistant Staphylococcus aureus
Q36584656Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat
Q40758601Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin
Q26823518European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid
Q49874675Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates
Q42445383Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations
Q41907664Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro
Q34058222Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus
Q41429045Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods
Q28477900Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR
Q41016957First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia
Q36439147Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus
Q34161745General principles of antimicrobial therapy
Q36932920Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus
Q38545589Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
Q24542412Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients
Q36452459Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin
Q37717901Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance
Q36692468Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance
Q33369409High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease
Q35123536High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis
Q34894900How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
Q98205022Human antimicrobial peptide, LL-37, induces non-inheritable reduced susceptibility to vancomycin in Staphylococcus aureus
Q42111799Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model
Q37263399Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.
Q36287998Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections.
Q35934534Importance of Decision Support Implementation in Emergency Department Vancomycin Dosing.
Q42653995Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility?
Q42738202In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates
Q42130598In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types
Q37263546In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus
Q40326741In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus
Q59811853Incidence and risk factors for potentially suboptimal serum concentrations of vancomycin during cardiac surgery
Q41066970Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period
Q37156698Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains
Q36416898Infective endocarditis treated with linezolid: case report and literature review.
Q46826194Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia
Q38019608Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs
Q35096913Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics
Q35023343Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia
Q38995472Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults
Q34894133Linezolid for the treatment of drug-resistant infections
Q37600404Linezolid: a review of safety and tolerability
Q40327481Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans
Q36025384Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.
Q37947249MRSA: the first half century
Q30234954Management and Novel Adjuncts of Necrotizing Soft Tissue Infections.
Q37700552Management of antibiotic resistance in the intensive care unit setting
Q36322109Management of healthcare-associated methicillin-resistant Staphylococcus aureus
Q37156709Management of methicillin-resistant Staphylococcus aureus bacteremia
Q34657311Mechanisms of antibiotic resistance in Staphylococcus aureus
Q80585586Medical treatment of endocarditis
Q54210717Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients: epidemiology and associated risk factors for morbidity and mortality.
Q35026548Methicillin-resistant Staphylococcus aureus in HIV-infected patients
Q36939685Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid.
Q42272352Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation
Q36328966Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains
Q34489407Mitigation of Staphylococcus aureus-mediated surgical site infections with ir photoactivated TiO2 coatings on Ti implants.
Q33500363Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients
Q33776656Necrosis of Staphylococcus aureus by the Electrospun Fe- and Ag-Doped TiO2 Nanofibers
Q43438833Necrotizing soft tissue infections in the intensive care unit
Q36953330New antimicrobial agents as therapy for resistant gram-positive cocci
Q37860558New trends in infective endocarditis
Q41873909Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus
Q36903680Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus
Q42943425Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus
Q90701768Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens
Q36777850Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections
Q42664007Pharmacokinetics of fusidic acid and cefepime in heart tissues: implications for a role in surgical prophylaxis
Q47634145Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.
Q38066654Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia
Q34529205Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.
Q33683520Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model
Q33826193Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of Staphylococcus aureus
Q36644689Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?
Q33602468Practical vancomycin dosing in hemodialysis patients in the era of emerging vancomycin resistance: a single-center experience
Q35940556Predictors of mortality in Staphylococcus aureus Bacteremia
Q36636699Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients
Q40085144Prevalence of Slow-growth Vancomycin Non-susceptibility In Methicillin-resistant Staphylococcus aureus
Q33974292Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine
Q37274726Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
Q61757039Prävention, Diagnose, Therapie und Nachsorge der Sepsis
Q34022843Quantitative determination of telavancin in pregnant baboon plasma by solid-phase extraction and LC-ESI-MS.
Q64131294Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico
Q37114426Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection
Q24646677Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications
Q38780029Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia
Q27011138Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections
Q35619094Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era
Q64131298Resumen de las recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos gram positivos en el paciente crítico
Q35038242Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure
Q37672039Rifampin combination therapy for nonmycobacterial infections
Q41479166Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection
Q36153912Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus
Q37860553Severe, non-bacteremic infections in ICU patients.
Q58694105Staphylococcus aureus bacteremia in a secondary level Spanish hospital: clinical implications of high vancomycin MIC
Q46800394Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid
Q37602845Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions
Q28481497Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model
Q37809666Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates
Q35905561Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).
Q37117865Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections
Q36787486The RpoB H₄₈₁Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus
Q34091829The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.
Q22065665The importance of the development of antibiotic resistance in Staphylococcus aureus
Q36328971The pharmacokinetic and pharmacodynamic properties of vancomycin
Q38084726The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults
Q37776832The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains
Q36779557The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus
Q34494676Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients
Q34910366Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
Q42743427Tolerance and heteroresistance in Gram-positive microorganisms
Q34630593Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing
Q37478888Transplacental transfer of vancomycin and telavancin
Q42914487Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria
Q36758570Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions
Q37681564Treatment strategies for infective endocarditis.
Q37322249Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics
Q34402839Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus
Q33909407USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit
Q37203845Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia
Q54392892Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?
Q43117809Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years
Q95355781Vancomycin Resistance in Staphylococcus aureus
Q42779344Vancomycin dosing in patients undergoing maintenance hemodialysis.
Q38462842Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice
Q34405301Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis
Q37340562Vancomycin resistance: are there better glycopeptides coming?
Q37236231Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory system
Q42153532Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates
Q38062923Vancomycin therapeutics and monitoring: a contemporary approach.
Q40483972Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer
Q43094503Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041.
Q34585059Vascular catheter-associated infections: a microbiological and therapeutic update.
Q38632488When sepsis persists: a review of MRSA bacteraemia salvage therapy
Q42197385daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations
Q33624615pH-Dependent Antimicrobial Properties of Copper Oxide Nanoparticles in Staphylococcus aureus

Search more.